In the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Over the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...

Markets ended flat on Thursday after a volatile session, with analysts maintaining a positive outlook and recommending a buy-on-dips strate...

Alembic Pharmaceuticals surged 12% to Rs 1,089.80 after securing USFDA approval for its generic Doxorubicin Hydrochloride Liposome Injectio...

Alembic Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Royalty Income and Other Operating R...

Earlier this month, the US drug regulator had issued a ‘Form 483’ to the facility of the drug company with five observations.

Revenue from operations rose to Rs 948.91 cr in Q1 as compared with Rs 862.53 cr a year ago.

"The company has received approval from the USFDA for its Abbreviated New Drug Application for Zolmitriptan Orally Disintegrating Tablets, ...

Although both the domestic and the international businesses are doing well, the company is likely to sustain its high growth largely on acc...

The third name, which we have liked for a long time, and had once recommended at Rs 40 level, is Caplin Point Laboratories.

100-year-old Vadodara-based firm, Alembic Pharmaceuticals is the second-best pharma stock in the BSE 500 in the past one year.

Vadodara-based drug maker, Alembic Pharmaceuticals will add more drugs to its domestic and international product basket this financial year.

"Alembic Pharma is a ‘BUY’ call with a target of Rs 135 and a stop loss of Rs 123."

There are 5 buy recommendations for the company's stock with a target price of Rs 99. The company's stock has hit the target price on Frida...

Alembic Pharmaceuticals posts 12% rise in Q2 net profit. Will add more to the basket of specialty products for growth.

Alembic has approved demerger of its pharmaceutical unit. The new entity Alembic Pharma will be listed on the exchanges post merger.